open access

Vol 14, No 4 (2010)
REVIEV
Published online: 2010-10-14
Get Citation

Effective prevention of cardiovascular events in high-risk patients - new indications for telmisartan

Joanna Dziwura, Krystyna Widecka
Nadciśnienie tętnicze 2010;14(4):332-343.

open access

Vol 14, No 4 (2010)
REVIEV
Published online: 2010-10-14

Abstract

Blockade of the renin–angiotensin–aldosterone system plays a pivotal role in the treatment of high blood pressure and prevention of target organ damage. Telmisartan is an angiotensin II receptor blocker displaying beneficial unique pharmacologic properties, metabolic effects, antihypertensive efficacy in monotherapy and combinations and good tolerance. Clinical studies confirm that telmisartan improves endothelial function, insulin sensitivity and lipid profiles, reduces arterial stiffness, left ventricular hypertrophy and the recurrence of atrial fibrillation. In addition, telmisartan improves renal function and has potential beneficial effects on prevention of cerebrovascular disease. The ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study has shown that telmisartan provides similar cardiovascular protection to ramipril in high-risk patients, while being better tolerated.
Arterial Hypertension 2010, vol. 14, no 4, pages 332-343.

Abstract

Blockade of the renin–angiotensin–aldosterone system plays a pivotal role in the treatment of high blood pressure and prevention of target organ damage. Telmisartan is an angiotensin II receptor blocker displaying beneficial unique pharmacologic properties, metabolic effects, antihypertensive efficacy in monotherapy and combinations and good tolerance. Clinical studies confirm that telmisartan improves endothelial function, insulin sensitivity and lipid profiles, reduces arterial stiffness, left ventricular hypertrophy and the recurrence of atrial fibrillation. In addition, telmisartan improves renal function and has potential beneficial effects on prevention of cerebrovascular disease. The ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study has shown that telmisartan provides similar cardiovascular protection to ramipril in high-risk patients, while being better tolerated.
Arterial Hypertension 2010, vol. 14, no 4, pages 332-343.
Get Citation

Keywords

telmisartan; hypertension; cardiovascular risk; ONTARGET

About this article
Title

Effective prevention of cardiovascular events in high-risk patients - new indications for telmisartan

Journal

Arterial Hypertension

Issue

Vol 14, No 4 (2010)

Pages

332-343

Published online

2010-10-14

Bibliographic record

Nadciśnienie tętnicze 2010;14(4):332-343.

Keywords

telmisartan
hypertension
cardiovascular risk
ONTARGET

Authors

Joanna Dziwura
Krystyna Widecka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl